Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Slides:



Advertisements
Similar presentations
Ted D. Williams PharmD Candidate OSU College of Pharmacy
Advertisements

Diabetes Control in Youth: The American Experience Georgeanna J. Klingensmith, MD Keystone Colorado July 2008.
Richard Croft Diabetes Lead Berkshire West. The impact of a 1% reduction in HbA1c.
INSULIN STRATEGIES IN TYPE 2 DIABETES. The epidemic of type 2 diabetes and the recognition that achieving specific glycemic goals can substantially reduce.
Dr. A. R. GOHARIAN Endocrinologist
Insulin therapy.
Basal-Bolus, Insulin Pumps, Carbohydrate Counting, Combination Therapy Dr.Ihab Tadros Medical Director Daisy Care Medical – USA The Leader in insulin Pump.
The Role of Modern Premixed Analogues in Clinical Practice Raef M. Botros Professor of Medicine Ain Shams University.
INSULIN THERAPY IN TYPE 1 DIABETES
PRE-EXISTING DIABETES AND PREGNANCY 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada.
Diabetes Technology Update
Closed-Loop Insulin Delivery in Children
Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes A double-tracer study.
Diabetes: What’s New? What’s Next? Robert P. Hoffman, M.D. Grand Rounds June 1, 2007.
Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
Endocrine and Metabolic Disorders Lectures 8 I.Kuziv, MD, PhD.
INSULIN PUMPS Shelby Polk DNP, FNP-BC, CDE. 2 MANAGEMENT OF DIABETES IN SCHOOLS Exercise Legal Rights Health & Learning Nutrition Insulin Administration.
Insulin Initiation With NovoMix30
Journal Club 亀田メディカルセンター 糖尿病内分泌内科 Diabetes and Endocrine Department, Kameda Medical Center 松田 昌文 Matsuda, Masafumi 2008 年5月1日 8:20-8:50 B 棟8階 カンファレンス室.
By Brooklyn Lancaster.  Type 1 Diabetes is a chronic condition in which the pancreas produces little or no insulin.  Without enough insulin, glucose.
ADDITIONAL SLIDES FOR ASSIST WITH COMPREHENSION OF LAB CONTENT-MODULE FIVE-DM DENISE TURNER, MS-N.ED, RN, CCRN.
Extra-Virgin Olive Oil Reduces Glycemic Response to a High–Glycemic Index Meal in Patients With Type 1 Diabetes: A Randomized Controlled Trial Featured.
Diabetes Mellitus Part 2 Kathy Martin DNP, RN, CNE.
Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes.
Date of download: 6/24/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Date of download: 6/26/2016 From: Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus: A Systematic.
Changes in the concentration of serum C-peptide in type 2 diabetes during long-term continuous subcutaneous insulin infusion therapy Department of Internal.
Representative insulin regimens for the treatment of diabetes
Key publication slides
CAN WE IMPROVE POSTPRANDIAL GLUCOSE CONTROL WITH FAST-ACTING INSULINS?
Achieving Optimal Glycaemic Control: Can Insulin Deliver?
Key publication slides
Baseline characteristics
Six Sensor CGM Array- Which do you trust?
Fig. 1 Examples of Insulin pump systems
Key publication slides
Type 1 Diabetes: Meters, Pumps, and Transitions to Adulthood
Moderator Stephen Atkin, MBBS, MD, PhD Professor of Medicine
Making the Case for Metabolic Surgery in Patients With Obesity and T2DM.
Patient Case 1 Peggy Peggy Interactive Case Question.
Faster-Acting Insulins
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Using the AGP to Standardize Glucose Reporting
T1DM: Insulin Initiation
New Patient-Friendly Options for Managing Insulin Dosing
Continuous Subcutaneous Insulin Infusion (CSII) [Insulin Pump]
Clinical recommendations in the management of the patient with type 1 diabetes on insulin pump therapy in the perioperative period: a primer for the anaesthetist 
Novel Concentrated Insulins: What Benefits and for Which Patients?
Updates to Managing Diabetes in the Long-Term Care Setting
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Sequential insulin strategies in type 2 diabetes.
Faster-Acting Insulins
21st century diabetes care: a marriage between humans and technology
Glucose Monitoring: An Evolving Landscape
Modern Advances in Glucose Monitoring
When Is Intrathecal Drug Delivery Appropriate?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Approach to starting and adjusting insulin in type 2 diabetes.
Hypoglycemia: The Most Common Barrier to Effective Diabetes Management
Liraglutide Shows CV Benefit: Clinical Perspectives on the LEADER Trial
Glucose Management and Statin Therapy
Glycemic Management in Adults with Type 1 Diabetes
Managing Hypoglycemia & Hyperglycemia
Government Funding of Diabetes Technologies
When Is Intrathecal Drug Delivery Appropriate?
Glucose Management and Statin Therapy
INSULINS Dr.R.Sajjad december INSULINS Dr.R.Sajjad december 2018.
A: PPG increment at week 26 for mealtime faster aspart versus IAsp.
CPPE Optimise: Insulins
Presentation transcript:

Utilizing New Technologies and Insulins for a Tighter Grip on PPG

Introduction/Overview

Major Mechanisms Linking Elevated PPG to Diabetes Complications

Recommended Targets for PPG

Diabetes Care Technologies: "Game Changers"

Patient Case Study

Smart Devices: CGM-Augmented Insulin Treatment

CGM From the Patient's Perspective

Optimizing Approaches to PPG Control

CSII: Insulin Pumps

Insulin Replacement Therapy Aims to Recreate the Normal Blood Insulin Profile

Ultra-Fast-Acting Insulins: Approaching a More Exact Physiologic Insulin Profile

Ultra-Fast-Acting Prandial Insulins

Trial of a Hybrid Closed-Loop Insulin Delivery System

The Challenge of Mimicking the Physiologic Response to Mealtime Glucose

BioChaperone® Lispro: Faster Insulin Kinetics Compared With Lispro (Injection)

Faster Aspart Pooled Analysis: Onset and Offset of Insulin Action

Patients With T1DM Who May Be Candidates for Ultra-Fast-Acting Insulins

Glucose-Monitoring With the FreeStyle Libre™ Device

Onset® 1: Study Design

Onset® 1: PPG (Test Meal)

Onset® 1: Faster-Acting Insulin Aspart Administered Postmeal

Onset® 4: Incidence of Hyperglycemia

Onset® 5: PPG Increment Results After a Standardized Meal Test

Scale of Self-Reported Psychological Complaints: Controls vs Patients With T1DM

Summary and Conclusions